Pulmonary Arterial Hypertension – Future Directions
Year: 2007
Type: article
Abstract: Pulmonary arterial hypertension (PAH) is a rare but life-threatening condition that has traditionally required treatment with continuous intravenous epoprostenol via an indwelling central catheter.1–3 Such therapy improves outcome, but is fraught with side effects, expense, and risk of catheter-related complications.
Source: US Cardiology Review
Author: Robert P Frantz
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,146
OpenAlex ID: W4238134444
